Tri- Or Tetrasaccharide Patents (Class 514/61)
-
Publication number: 20080214499Abstract: The object of the present invention is to provide a lipid-regulating agent or a composition for regulating the amount of lipids comprising the agent. The present invention solves the above object by providing a lipid-regulating agent comprising a cyclic tetrasaccharide and/or its saccharide-derivative(s) and a composition for regulating the amount of lipids comprising the lipid-regulating agent.Type: ApplicationFiled: February 19, 2008Publication date: September 4, 2008Applicant: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kazuyuki Oku, Michio Kubota, Shigeharu Fukuda, Toshio Miyake
-
Publication number: 20080207559Abstract: A carbohydrate mixture for dietetic foods and pharmaceuticals containing several carbohydrates is provided according to the present invention. Said carbohydrate mixture is characterized in that they contain or consist of two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed, that said carbohydrate component A is composed of at least one monosaccharide or of at least one oligosaccharide (disaccharide to hexasaccharide) or of a mixture of two or more of these saccharides, that the carbohydrate component B is composed of a polysaccharide (from heptasaccharide onwards) or of a mixture of two or more polysaccharides, that the carbohydrate component A=5 to 95 wt-% and the carbohydrate component B=5 to 95 wt-% of the sum of the carbohydrate components A+B (=100 wt-%), and that at least 80 wt-% of the carbohydrates/saccharides of the carbohydrate components A and B have a prebiotic effect.Type: ApplicationFiled: April 30, 2008Publication date: August 28, 2008Applicant: N.V. NutriciaInventors: Gunther Sawatzki, Bernd Stahl
-
Patent number: 7417031Abstract: Medicinal compositions for treating, ameliorating or preventing diseases with sensitivity to 3,6-anhydrogalactopyranose represented by formula (1): foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity and inhibitory activities on the production of active oxygen, lipid peroxide radicals and NO, which makes it useful also as the active ingredient of antioxidants and preservatives.Type: GrantFiled: January 13, 2005Date of Patent: August 26, 2008Assignee: Takara Bio Inc.Inventors: Tatsui Enoki, Hiroaki Sagawa, Takanari Tominaga, Eiji Nishiyama, Nobuto Koyama, Takeshi Sakai, Fu-Gong Yu, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 7402575Abstract: Methods and compositions for treating myocardial dysfunction or inflammation are described. The methods of the invention involve administering an agent that can inhibit lysozyme to an animal in need thereof. Preferred lysozyme inhibitors include TAC and chitobiose.Type: GrantFiled: January 23, 2004Date of Patent: July 22, 2008Inventors: Steven N. Mink, Hans Jacobs, Deepak Bose, Krika Duke, R. Bruce Light
-
Publication number: 20080171721Abstract: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.Type: ApplicationFiled: September 14, 2007Publication date: July 17, 2008Inventor: Bahram Memarzadeh
-
Publication number: 20080124323Abstract: The present invention provides a method and composition for the treatment and/or prevention of respiratory tract infection and/or respiratory tract infection disease, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and at least 5 wt. % digestible galactose saccharide.Type: ApplicationFiled: August 24, 2005Publication date: May 29, 2008Inventors: Gunther Boehm, Laura M'Rabet, Bernd Stahl, Johan Garssen
-
Patent number: 7375095Abstract: For extending the uses of a compound represented by Chemical formula 1, the object of the present invention is to provide a derivative of cyclic tetrasaccharide whose physicochemical properties are changed from those of cyclic tetrasaccaride, a composition comprising the same, and a process for producing the same. The present invention solves the above object by providing a derivative of cyclic tetrasaccharide, which is produced by the steps of reacting a compound represented by Chemical formula 1 with a reactive reagent and substituting one ore more hydroxyl groups with substituents except hydroxyl group and O-glycosyl group; a composition comprising the same; and a process for producing the derivative of cyclic tetrasaccharide.Type: GrantFiled: November 19, 2002Date of Patent: May 20, 2008Assignee: Kabashiki Kaisha Hayashibara Seibutsu KagakuInventors: Kazuyuki Oku, Naoki Kudo, Shigeharu Fukuda
-
Patent number: 7365192Abstract: The present invention provides a preparation method of valienamine from acarbose or acarbose derivatives using organic acid TFA (trifluoroacetic acid). By using the method of the present invention, valienamine, the core precursor of voglibose which is a strong retardant of ?-glucosidase and which is used for the cure of diabetes, can be produced in large quantities by using selective hydrolysis from acarbose or acarbose derivatives using TFA.Type: GrantFiled: November 23, 2002Date of Patent: April 29, 2008Assignee: B T Gin, Inc.Inventors: Youl Her, Jin-Hwan Oh
-
Patent number: 7365191Abstract: This invention involves a type of oligosacoharides and its their sulfate derivatives. The backbone of the oligosaccharides consists of 4 to 14 glucose residues, while the side chains contain 0 to 4 glucose residues. There are at least one 1->3? linkage and ?-(1->3)-Iinkage or ?-(1->4) linkage in the backbone. These oligosaccharides, and their sulfates have immune enhancing, antitumor, and antiviral activities. They can be used in immune enhancing, antitumor, and antiviral medicine compounds that would be used as therapeutic treatments.Type: GrantFiled: July 5, 2002Date of Patent: April 29, 2008Assignee: Shanghaimed Co., LtdInventors: Fanzuo Kong, Jun Ning, Jianxin Gu
-
Publication number: 20080095752Abstract: The invention involves a method for extending the shelf life of a powdered nutritional formulation that contains LGG by reducing and maintaining a threshold water activity or moisture content in the powdered LGG-containing formulation.Type: ApplicationFiled: October 20, 2006Publication date: April 24, 2008Inventors: Win-Chin Chiang, Bryon W. Petschow, Adrie Baars, Yung H. Lee, Luis Jose Montelongo, Nagendra Rangavajla
-
Patent number: 7361744Abstract: Compounds having the formula (I): wherein A represents a group such as a cyclic group, R1 and R2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.Type: GrantFiled: July 28, 2005Date of Patent: April 22, 2008Assignee: Sankyo Company LimitedInventors: Takeshi Honda, Akira Okuno, Masanori Izumi, Xiaoliu Li
-
Patent number: 7326182Abstract: Bio-affinity material containing at least one biologically active saccharide which is covalently bound via at least one spacer to a cross-linked matrix and that the material is autoclaved. Apparatus for contacting body fluids with the bio-affinity material is disclosed.Type: GrantFiled: December 15, 2005Date of Patent: February 5, 2008Assignee: Glycorex Transplantation ABInventor: Kurt G. L. Nilsson
-
Patent number: 7309697Abstract: An object of the present invention is to provide an option of non-reducing saccharide by providing a novel non-reducing saccharide composed of glucose as constituents and to provide a novel enzyme forming the non-reducing saccharide, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the non-reducing saccharide, and uses thereof. The present invention solves the above object by providing a novel cyclic saccharide having a structure of cyclo{?6)-?-D-glucopyranosyl-(1?4)-?-D-glucopyranosyl-(1?6)-?-D-glucopyranosyl-(1?4)-?-D-glucopyranosyl-(1?6}, cyclic maltosylmaltose, novel cyclic maltosylmaltose-forming enzyme, a method and process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, a composition comprising the cyclic maltosylmaltose or a saccharide composition comprising the same, and uses thereof.Type: GrantFiled: August 26, 2004Date of Patent: December 18, 2007Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Kazuhisa Mukai, Hikaru Watanabe, Tomoyuki Nishimoto, Michio Kubota, Shigeharu Fukuda, Toshio Miyake
-
Patent number: 7297680Abstract: Disclosed are immortalized human embryonic retina cells, having a nucleic acid sequence encoding an adenoviral E1A protein integrated into the genome of the cells, and further comprising a nucleic acid sequence encoding an enzyme involved in post-translational modification of proteins, such as a sialyltransferase, wherein said nucleic acid sequence encoding the enzyme involved in post-translational modification of proteins is under control of a heterologous promoter. Methods for producing recombinant proteins from such cells and obtaining such recombinant proteins having increased sialylation are provided as are novel compositions of isoforms of erythropoietin.Type: GrantFiled: April 8, 2005Date of Patent: November 20, 2007Assignee: Crucell Holland B.V.Inventors: Dirk J. E. Opstelten, Alphonsus G. C. M. UytdeHaag
-
Patent number: 7291607Abstract: Isomaltooligosaccharides (IMOs) produced by Leuconostoc mesenteroides ATCC 13146 fermentation with a sucrose:maltose ratio of 2:1 have been discovered to be effective prebiotics in mixed cultures of microbial populations, including cultures from chicken ceca. Surprisingly in mixed microbial cultures this IMO composition proved as effective as FOS. Thus, these IMOs can be used as effective prebiotics for both birds and mammals. Moreover, the IMOs were discovered to be effective non-competitive inhibitors of ?-glucosidase. These IMOs also will be useful, as an ?-glucosidase inhibitor, in a therapeutic application for several diseases, including obesity, diabetes mellitus, pre-diabetes, gastritis, gastric ulcer, duodenal ulcer, caries, cancer, viral disease such as hepatitis B and C, HIV, and AIDS. A diet with 5-20% IMOs was also shown to reduce the abdominal fat tissue in mammals.Type: GrantFiled: May 19, 2004Date of Patent: November 6, 2007Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventors: Donal F. Day, Chang-Ho Chung
-
Publication number: 20070244069Abstract: Provided herein are methods of using mannan oligosaccharides, to treat, palliate, relieve, prevent and/or eliminate urinary tract infections of humans. A mixture of oligosaccharides derived from yeast cell walls is shown to reduce, eliminate and prevent the symptoms of UTI in patients.Type: ApplicationFiled: October 6, 2006Publication date: October 18, 2007Inventors: Richard Katz, Clair Brown
-
Patent number: 7271158Abstract: The invention described herein relates to: the use of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in the manufacture of a composition for the treatment of acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase to a ruminant; a formulation suitable for the treatment of acidosis in an animal which comprises an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial ?-amylase and/or ?-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacterial ?-amylaType: GrantFiled: February 6, 2004Date of Patent: September 18, 2007Assignee: Pfizer Inc.Inventors: Bernard Joseph Banks, Mark Andrew Haxell, Graham Lunn, Michael Stephen Pacey, Lee Richard Roberts
-
Patent number: 7192937Abstract: The use of compositions containing one or more oligosaccharides in an amount effective to disinfect and/or preserve medical devices, pharmaceutical preparations, and the like is described. Buffered solutions containing one or more oligosaccharide-containing compositions and methods of making and using the same are also described.Type: GrantFiled: May 19, 2004Date of Patent: March 20, 2007Assignee: Bausch & Lomb IncorporatedInventor: Erning Xia
-
Patent number: 7182954Abstract: Oligosaccharides produced by an alternansucrase enzyme catalyzed reaction of sucrose with an acceptor oligosaccharide are effective as prebiotics for controlling enteric bacterial pathogens. Populations of enteropathogenic bacteria may be substantially reduced or inhibited by treatment of an animal with a composition comprising one or more of these oligosaccharides in an amount effective to promote the growth of beneficial bacteria. The method is particularly effective for the control of Salmonella species, enteropathogenic Escherichia coli, and Clostridia perfringens.Type: GrantFiled: April 4, 2003Date of Patent: February 27, 2007Assignees: The United States of America, as represented by the Secretary of Agriculture, Board of Trustees of Western Illinois Univ.Inventors: Gregory L. Cote, Scott M. Holt
-
Patent number: 7166582Abstract: The present invention provides a sate and excellent antiallergic composition, and more particularly a preventive and therapeutic composition for atopic dermatitis, including an antiallergic composition blended with stachyose as an effective ingredient, and a medicine, food and beverage containing the composition.Type: GrantFiled: July 25, 2005Date of Patent: January 23, 2007Assignee: J-Oil Mills, Inc.Inventors: Toshiro Sato, Shuichi Kamo, Yutaka Ohtani, Yasushi Ueno
-
Patent number: 7163672Abstract: The invention relates to a pharmaceutical aerosol formulation comprising a surfactant that is an alkyl-polyglycoside of formula I, wherein DP is the average degree of polymerisation and has a value of from 1 to 4, and R is an alkyl chain or a mixture of alkyl chains having a chain length of from 6 to 22 carbon atoms; or a derivative thereof for the administration of a medicament for inhalation.Type: GrantFiled: December 19, 2001Date of Patent: January 16, 2007Assignee: AstraZeneca ABInventors: Graham Buckton, Angela Columbano, Martin Grosvenor, Philip Wikeley
-
Patent number: 7157431Abstract: Compositions of plant carbohydrates for dietary supplements and nutritional support for promotion and maintenance of good health. Defined nutritionally effective amounts of one to eleven essential saccharides, glyconutrients, are used in various inventive compositions as dietary supplements. The dietary composition herein can include phytonutrients, vitamins, minerals, herbal extracts, and other non-toxic nutrients. The glyconutritional dietary supplement herein provides essential saccharides which are the building blocks of glycoproteins. These compositions, when administered orally or topically, have been found to improve the well being of mammals suffering from a variety of disorders.Type: GrantFiled: March 10, 2004Date of Patent: January 2, 2007Assignee: Mannatech, Inc.Inventors: Bill H. McAnalley, H. Reginald McDaniel, D. Eric Moore, Eileen P. Vennum, William C. Fioretti
-
Patent number: 7119079Abstract: Disclosed are compounds having the formula wherein R2 is hydrogen, a monomeric glycoside or an oligomeric glycoside, R3 is hydrogen, a monomeric glycoside, an oligomeric glycoside, or a group having the formula R is a lower alkylene, R? is selected from the group consisting of moieties having the formula where X=0 or 1, Y=0 or 1, R1 is hydrogen or a pharmacologically active drug residue, R8 a pharmacologically active drug residue, R4, R5, and R6 are independently hydrogen, alkyl, aryl, aralkyl, and cycloalkyl or together form a nitrogen-containing ring, and R7 is hydroxyl or hydroxyalkyl.Type: GrantFiled: January 20, 2004Date of Patent: October 10, 2006Inventor: Donald L. Barbeau
-
Patent number: 7109182Abstract: A pharmaceutical composition including a therapeutically effective amount of at least one oligomannoside produced by chemical synthesis which is homologous to a wall oligomannoside of an infectious organism or pathogen, or a derivative thereof, and a pharmaceutically acceptable vehicle.Type: GrantFiled: May 23, 2002Date of Patent: September 19, 2006Assignee: Centre Hospitalier Regional Universitaire (CHRU)Inventors: Jacques Esnault, Pierre Sinay, Reynald Chevalier, Jean-Frédéric Colombel, Jean-Maurice Mallet, Boualem Sendid, Thierry Jouault, Daniel Poulain, Pierre-André Trinel
-
Patent number: 7105178Abstract: A cardiotonic composition includes micronized digoxin, hydrophilic polymer(s) and optionally pharmaceutically acceptable excipient(s) in the form of a tablet that releases not more than 50% digoxin in 5 minutes and at least 85% digoxin in 60 minutes.Type: GrantFiled: December 7, 2001Date of Patent: September 12, 2006Assignee: Sun Pharmaceutical Industries LimitedInventors: Nitin Bhalachandra Dharmadhikari, Vaishali Vijay Dhavse
-
Patent number: 7101859Abstract: The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels.Type: GrantFiled: July 28, 2003Date of Patent: September 5, 2006Assignee: Yissum Research Development Company of The Hebrew University of JerusalemInventors: Saul Yedgar, Miron Krimsky, Grietje Beck, Benito Antonio Yard, Fokko Johannes van der Woude
-
Patent number: 7070778Abstract: The present invention relates to compositions and methods for treating humans and warm-blood animals suffering from cancer. More particularly, a therapeutical treatment in which a monoclonal antibody is administered with either ?-(1,3)-glucan like laminarin or a oligo-?-(1,3)-glucan and a pharmaceutically acceptable carrier, to patients suffering from cancer are described.Type: GrantFiled: October 30, 2003Date of Patent: July 4, 2006Assignee: Laboratoire Goemar SAInventors: Jean-Claude Yvin, Edouard Panak, Vaclav Vetvicka
-
Patent number: 7056678Abstract: The invention provides a method for the structural analysis of a saccharide, comprising: a) providing on a surface a plurality of essentially sequence- and/or site-specific binding agents; b) contacting said surface with a saccharide to be analyzed, or with a mixture comprising a plurality of fragments of said saccharide; c) washing or otherwise removing unbound saccharide or saccharide fragments; d) adding to the surface obtained in step c) an essentially sequence- and/or site-specific marker, or a mixture of essentially sequence- and/or site-specific markers; e) acquiring one or more images of the markers that are bound to said surface; and f) deriving information related to the identity of the saccharide being analyzed from said image.Type: GrantFiled: May 4, 2000Date of Patent: June 6, 2006Assignee: Procognia LTDInventor: Ofer Markman
-
Patent number: 7041656Abstract: An enzyme which decomposes a sulfated fucoglucuronomannan and is useful in the field of glycotechnology; a process for producing the enzyme; a fucoidan fraction reduced in the number of the kinds of molecules and useful as a reagent in glycotechnology; a sulfated fucoglucuronomannan oligosaccharide; and processes for producing the fraction and oligosaccharide.Type: GrantFiled: April 18, 2002Date of Patent: May 9, 2006Assignee: Takara Bio Inc.Inventors: Takeshi Sakai, Hitomi Kimura, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 7034006Abstract: The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels.Type: GrantFiled: January 10, 2001Date of Patent: April 25, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Saul Yedgar, David Shuseyov, Gershon Golomb, Reuven Reich, Isaac Ginsburg, Abd-al-Roof Higazi, Moshe Ligumski, Miron Krimsky, David Ojcius, Benito Antonio Yard, Fokko Johannes van der Woude, Edit Schnitzer
-
Patent number: 7015206Abstract: The invention concerns the use of a polysaccharide excreted by the Vibrio diabolicus species for making a medicine with cicatrising activity, in particular bone repair activity. The invention also concerns a bone reconstruction biomaterial comprising said polysaccharide and a bone endoprosthesis whereof the surface is coated with such a polysaccharide.Type: GrantFiled: July 4, 2001Date of Patent: March 21, 2006Assignee: Institut Francais de le Recherche pour l'Exploitation de la MerInventors: Jean Guezennec, Philippe Zanchetta
-
Patent number: 6984630Abstract: The invention concerns endofucanases suitable for preparing fuco-oligosaccharides by enzymatic hydrolysis of fucanes. It also concerns a bacterium producing endofucanases and the preparation of said enzyme from the bacterium. It further concerns endofucanase genes and it finally concerns the use said fuco-oligosaccharides for plant protection.Type: GrantFiled: September 21, 1999Date of Patent: January 10, 2006Assignee: Laboratoires GOEMAR S.A.Inventors: Valérie Descamps, Olivier Klarszinsky, Tristan Barbeyron, Bernard Cloarec, Bernard Fritig, Jean-Marie Joubert, Bertrand Plesse, Jean-Claude Yvin
-
Patent number: 6946451Abstract: Provided are a method for promoting insulin secretion, a method for suppressing the elevation of a blood glucose level, a method for ameliorating diabetes mellitus, a method for promoting growth of an animal, and a method for increasing an insulin level in breast milk. These methods comprising administering at least one member selected from the group consisting of a di- or a higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof, to a patient in need thereof or an animal.Type: GrantFiled: February 3, 2003Date of Patent: September 20, 2005Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Miho Takada, Toshikazu Kamiya, Tetsuo Endo, Satoshi Koizumi
-
Patent number: 6936598Abstract: A method for reducing the quantity of Desulfovibrio and/or Helicobacter spp. in the GI tract of a companion pet which comprises orally administering to the said pet a Desulfovibrio and/or Helicobacter spp. reducing quantity of a fiber or other component.Type: GrantFiled: November 21, 2003Date of Patent: August 30, 2005Assignee: Hill's Pet Nutrition, Inc.Inventors: Christina Khoo, Kathy Lynn Gross, Glenn Gibson
-
Patent number: 6929807Abstract: Compositions of plant carbohydrates for dietary supplements and nutritional support for promotion and maintenance of good health. Defined nutritionally effective amounts of one to eleven essential saccharides, glyconutrients, are used in various inventive compositions as dietary supplements. The dietary composition herein can include phytonutrients, vitamins, minerals, herbal extracts, and other non-toxic nutrients. The glyconutritional dietary supplement herein provides essential saccharides which are the building blocks of glycoproteins. These compositions, when administered orally or topically, have been found to improve the well being of mammals suffering from a variety of disorders.Type: GrantFiled: August 4, 1997Date of Patent: August 16, 2005Assignee: Mannatech, Inc.Inventors: Bill H. McAnalley, H. Reginald McDaniel, D. Eric Moore, Eileen P. Vennum, William C. Fioretti
-
Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
Patent number: 6911436Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates and natural or synthetic essential oils can work effectively as a topical pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion cascade.Type: GrantFiled: June 15, 2001Date of Patent: June 28, 2005Assignee: Dermal Reserach Laboratories, Inc.Inventors: Harold G. Brown, Karen K. Brown -
Patent number: 6897198Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described. Also described are compounds of formula I in which the radicals have the abovementioned meanings, and their physiologically tolerated salts, physiologically functional derivates and processes for their preparation. The compounds are suitable as, for example, hypolipidemics.Type: GrantFiled: January 27, 2003Date of Patent: May 24, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Wendelin Frick, Reinhard Kirsch, Heiner Glombik, Werner Kramer, Hans-Ludwig Schäfer
-
Publication number: 20040254145Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids, which include a portion or analogue thereof) linked to a carbohydrate or glycomimetic.Type: ApplicationFiled: May 16, 2003Publication date: December 16, 2004Applicant: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, Leonard M. Williams
-
Publication number: 20040248848Abstract: The the use of a dose of 2.5 mg of the pentasaccharide methyl O-(2-deoxy-2-sulfoamino-6-O-sulfo-&agr;-D-glucopyranosyl)-(1→4)-O-(&bgr;-D-glucopyranosyl uronic acid)-(1→4)-O-(2-deoxy-2-sulfoamino-3,6-di-O-sulfo-&agr;-D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-&agr;L-idopyranosyl uronic acid)-(1→4)-2-deoxy-2-sulfoamino-6-O-sulfo-&agr;-D-glucopyranoside decasodium salt for the treatment of Acute Coronary Syndromes (ACS).Type: ApplicationFiled: April 8, 2004Publication date: December 9, 2004Inventor: Anthonie Wilhelmus Arnold Lensing
-
Patent number: 6825173Abstract: The present invention describes isolated Fagopyritol A1, isolated Fagopyritol A3, and isolated Fagopyritol B3. Compositions which include two or more of Fagopyritol A1, Fagopyritol A2, Fagopyritol A3, Fagopyritol B1, Fagopyritol B2, Fagopyritol B3, and D-chiro-inositol, at least one of which is an isolated Fagopyritol A1, isolated Fagopyritol A3, or isolated Fagopyritol B3, are also disclosed. Methods for preparing substantially pure Fagopyritol A1, Fagopyritol A3, Fagopyritol B3, or mixtures thereof from buckwheat are also described. The fagopyritols can be used to prepare pharmaceutical compositions, the administration of which can be used to treat diabetes.Type: GrantFiled: July 10, 2002Date of Patent: November 30, 2004Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Marcin Horbowicz
-
Publication number: 20040219206Abstract: The present invention encompasses a solid dose delivery vehicle for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, the delivery vehicle being sized and shaped for penetrating the epidermis. The delivery vehicle further comprises a stabilizing polyol glass loaded with the bioactive material and capable of releasing the bioactive material in situ. The present invention further includes methods of making and using the solid dose delivery vehicle of the invention.Type: ApplicationFiled: May 28, 2004Publication date: November 4, 2004Inventors: Bruce J. Roser, Jaap Kampinga, Camilo Colaco, Julian Blair
-
Publication number: 20040208859Abstract: The present invention provides a bile acid absorbent/adsorbent comprising as active ingredients a lactic acid bacterium having a property of incorporating bile acids into the cell in the presence of an oligosaccharide and of no releasing them out of the cells, and the oligosaccharide. The lactic acid bacterium includes Lactobacillus salivarius ssp. salicinius strain JCM1044, Bifidobacterium breve strain JCM1192, etc. The oligosaccharide includes raffinose, kestose, nystose, trehalose, etc. The bile acid adsorbent is in a form of oral formulation, or eatables and drinkables, etc. The bile acid absorbent/adsorbent can be utilized as cholesterol lowering agents or colorectal cancer inhibitors.Type: ApplicationFiled: March 2, 2004Publication date: October 21, 2004Inventors: Atsushi Yokota, Fusao Tomita, Kouji sayama, Yasunori Hukumori
-
Publication number: 20040180827Abstract: Lyophilized compositions of TFPI or a TFPI variant suitable for long-term storage can be formed by lyophilizing an aqueous formulation of the TFPI or TFPI variant having a pH from about 4 to about 8 with a carbohydrate or amino acid glass forming agent. These lyophilized compositions are stable for greater than three months when stored at 40° C.Type: ApplicationFiled: January 8, 2004Publication date: September 16, 2004Applicant: Chiron CorporationInventors: Bao-Lu Chen, Maninder Hora
-
Publication number: 20040137082Abstract: Compounds and methods are provided for reducing myostatin concentration. The compounds include an extract of Cystoseira canariensis having at least one sulfated polysaccharide. Each of the at least one sulfated polysaccharides preferably has fewer than nine saccharide units. The compounds also may include fluorotannins, fluoroglucinols or both.Type: ApplicationFiled: January 9, 2003Publication date: July 15, 2004Inventor: Zakir Ramazanov
-
Publication number: 20040121984Abstract: Oligosaccharides specific for Chlamydia mediate attachment of the organism to host cells.Type: ApplicationFiled: November 18, 2003Publication date: June 24, 2004Applicant: The University of WashingtonInventors: Cho-Chou Kuo, Albertina F. Swanson, Sen-Itiroh Hakomori, Noriko Takahashi
-
Publication number: 20040116339Abstract: The invention provides peptides and compounds that can bind to P2Y2 receptors that are useful for modulating the secretion of mucus within mucosal surfaces.Type: ApplicationFiled: December 16, 2002Publication date: June 17, 2004Inventors: Julie M. Villanueva, Stephen Quirk
-
Publication number: 20040110721Abstract: The present invention relates to a pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina which comprises sucrose and/to maltose, to the use of certain sucrose and/or maltose, in preparing the pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina, in particular to a method of stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina, treating the reduction of gram-positive bacilli and the lowness of acidity in vagina as well as the vaginitis and the disturbance of vaginal bacterioflora accompanying the reduction of gram-positive bacilli, especially bacterial vaginal disease.Type: ApplicationFiled: August 18, 2003Publication date: June 10, 2004Applicants: Shanghai Jiao Da Onlly Co., Ltd., Zhongming ZengInventor: Zhongming Zeng
-
Patent number: 6747010Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: GrantFiled: January 2, 2003Date of Patent: June 8, 2004Assignee: Kirin Beer Kabushiki KaishaInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka
-
Publication number: 20040102416Abstract: The present invention provides a safe and excellent antiallergic composition, and more particularly a preventive and therapeutic composition for atopic dermatitis, including an antiallergic composition blended with stachyose as an effective ingredient, and a medicine, food and beverage containing the composition.Type: ApplicationFiled: November 7, 2003Publication date: May 27, 2004Applicant: KABUSHIKI KAISHA HONEN CORPORATIONInventors: Toshiro Sato, Shuichi Kamo, Yutaka Ohtani, Yasushi Ueno
-
Patent number: RE39245Abstract: The present invention relates to simplified synthesis, new carbohydrate-based products and practical use of different carbohydrate-based products. Examples of these are (Gal?1-3Gal), GlcNAc?1-3Gal, ?- or ?-glycosides thereof, Gal?1-3Gal- containing tri-, or higher oligosaccharides, ?- or ?-glycosides thereof, GlcNAc?1-3Gal containing tri-, tetra-, or higher oligosaccharides, and derivatives and/or ?- or ?-glycosides thereof, Gal?1-3GalGlcNAc?1-3Gal, ?- or ?-glycosides thereof, Gal?1-3Gal?1-4GlcNAc?1-3Gal?1-4Glc, or other higher oligosaccharides containing the Gal?1-3Gal-structure, ?- or ?-glycosides thereof, modified carbohydrates, di-, tri-, oligo-, or polyfunctional products containing carbohydrate structures, and the use of the products for synthesis, affinity purification, diagnostic applications and therapy.Type: GrantFiled: December 23, 1996Date of Patent: August 22, 2006Assignee: Procur ABInventor: Kurt Nilsson